Given that different microRNAs targeting inflammation and liver fibrosis were altered in the steatotic and Ex-4 treated steatotic HepG2 cells, one cannot exclude a potential in vivo effect of the GLP-1R agonists on the miRNAs profiles in Kupffer cells and HSCs to lower inflammation and liver fibrosis and thus improve NAFLD. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatotic liver disease.